

Superb Performance in

Respiratory

Tract Infections



MACLARA
(Clarithromycin)

Tablets 250mg
Suspension 125mg/5ml

MACLARA (Clarithromycin)

Tablets 250mg

Suspension 125mg/5ml (60ml Bottle)

- ▶ *Proven clinical efficacy*
- ▶ *Highly effective in both upper and lower RTIs*
- ▶ *Right choice for H. pylori combination therapy*
- ▶ *Rapid Absorption from G I Tract*
- ▶ *Excellent Tolerance*
- ▶ *Convenient BD Dosage*
- ▶ *Better Compliance*

INDICATIONS:

- ▶ **Upper Respiratory Tract Infections:**
Pharyngitis, Sinusitis, Otitis Media, etc.
- ▶ **Lower Respiratory Tract Infections:**
Bronchitis, Pneumonia, etc.
- ▶ **Skin & Soft Tissue Infections :**
Folliculitis, Cellulitis, Erysipelas, etc.
- ▶ **Disseminated or Localized Mycobacterial Infections.**
- ▶ **H. pylori infected Peptic ulcer diseases.**
- ▶ **Odontogenic Infections.**

Brief Prescribing Informations:

Composition: Each Maclara 250mg tablet contains Clarithromycin 250mg and each 5ml reconstituted suspension contains Clarithromycin 125mg/5ml. **Indications:** Maclara (Clarithromycin) is indicated for the treatment due to susceptible organisms. Such indications include: 1) Lower respiratory tract infections (e.g. bronchitis, pneumonia) 2) Upper respiratory tract infections (e.g. pharyngitis, sinusitis) 3) E.N.T. infections (e.g. Acute otitis Media) 4) infections due to Mycobacterium avium or Mycobacterium intracellulare. 5) Localized infections due to Mycobacterium chelonae, Mycobacterium fortuitum or Mycobacterium kansasii. 6) Clarithromycin (Maclara) is indicated for the prevention of disseminated Mycobacterium avium complex infection in HIV - infected patient with CD4 lymphocyte counts less than or equal to 100/mm³ 7) Clarithromycin (Maclara) is indicated for the treatment of H. Pylori infected recurrent duodenal ulcer 8) Treatment of odontogenic infections. **Contraindications** Clarithromycin is contraindicated in patients having hypersensitivity to this class of antibiotics. Concomitant administration of Clarithromycin with astemizole, cisapride, pimozide and terfenadine is also contraindicated. **Warnings:** Particularly during the first 3 months of pregnancy, the physician should not prescribe Clarithromycin without considering the benefits against risk. The risk of Pseudomonas colitis is associated with nearly all antibiotic agents including macrolides, and may range from mild to severe and to life threatening conditions. **Precautions:** Caution should be exercised in administering the drug to patients with impaired hepatic function since the drug is principally excreted by the liver. Similarly, caution is required in cases of mild to severe renal impairment too. Attention should also be paid to the possibility of cross-resistance between Clarithromycin and other drugs of the same class (Macrolides) as well as lincosamides and clindamycin. **Usage During Pregnancy and Lactation:** The safety profiles of Clarithromycin have not been established during pregnancy and breastfeeding of infants, since the drug is excreted into human breast milk. **Adverse Reactions:** The clinical studies showed the following adverse effects in adults and children with Clarithromycin i.e. gastrointestinal related complaints (nausea, dyspepsia and abdominal pain, vomiting and diarrhoea). Other adverse effects include headache, taste perversion and transient elevations of liver enzymes. **Dosage and Administration: Adults:** The usual recommended dose is 250mg tablets BID this dose can be increased to 500mg twice daily depending on severity of infections. The recommended duration of therapy is 5 to 14 days with the exception of community acquire pneumonia and sinusitis where the duration will be 6 to 14 days. **Children:** The recommended daily dosage of Clarithromycin suspension in children is 7.5mg/kg BID upto a maximum dose of 500mg BID for non-Mycobacterial infections. The recommended duration of therapy is 5 to 10 days depending on the pathogen involved & the severity of the conditions. The prepared suspension can be taken with or without meals & with milk. **Presentation:** Maclara 250mg Tablets 10's. Maclara Suspension 125mg/5ml (60ml Bottle) (Oral Dry Suspension). **References:** 1) J Pak Med Assoc. 2003 Aug ; 53 (8) : 338-45 2) Post Graduate Medicine 2001 Sep ; Vol 110 (3) 3. Am Fam Physician 2002 July 1; 66(1): 119-24



Tutti Frutti
Flavour

'Medicines For All'



Zafa Pharmaceutical Laboratories (Private) Limited.

L-1/B, Block-22, FEDERAL 'B' INDUSTRIAL AREA, KARACHI-75950 (PAKISTAN)

Email: zafaph@cyber.net.pk. Website: www.zafa.com.pk



ISO 9001:2000